Adrecizumab in Cardiogenic Shock

Clinical trial NCT03989531 · COMPLETED

Trial details

NCT number: NCT03989531
Sponsor: Dr. med. Mahir Karakas
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Cardiogenic Shock Endothelial Dysfunction

Start date: 2019-04-04
Primary completion: 2021-04-26
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.